Zacks: Analysts Expect Five Prime Therapeutics Inc (NASDAQ:FPRX) Will Announce Earnings of -$0.86 Per Share

Equities research analysts expect Five Prime Therapeutics Inc (NASDAQ:FPRX) to report earnings of ($0.86) per share for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Five Prime Therapeutics’ earnings, with estimates ranging from ($1.18) to ($0.37). Five Prime Therapeutics posted earnings per share of ($0.99) during the same quarter last year, which would suggest a positive year-over-year growth rate of 13.1%. The business is expected to announce its next quarterly earnings results on Wednesday, August 14th.

According to Zacks, analysts expect that Five Prime Therapeutics will report full-year earnings of ($3.75) per share for the current financial year, with EPS estimates ranging from ($4.65) to ($3.09). For the next year, analysts expect that the business will report earnings of ($2.81) per share, with EPS estimates ranging from ($4.07) to ($1.59). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.02) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.07) by $0.05. The firm had revenue of $5.35 million during the quarter, compared to analysts’ expectations of $5.71 million. Five Prime Therapeutics had a negative return on equity of 54.87% and a negative net margin of 683.89%.

A number of equities analysts have weighed in on FPRX shares. Zacks Investment Research lowered Eisai from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 24th. Guggenheim lowered Anadarko Petroleum from a “buy” rating to a “hold” rating and set a $69.00 price target on the stock. in a research note on Friday, April 12th. ValuEngine lowered Zumiez from a “hold” rating to a “sell” rating in a research note on Monday, May 13th. Wells Fargo & Co decreased their price target on Cummins from $175.00 to $165.00 and set a “market perform” rating on the stock in a research note on Monday, June 3rd. Finally, Roth Capital began coverage on Forty Seven in a research note on Wednesday, May 29th. They issued a “buy” rating and a $28.00 price target on the stock. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $20.00.

Several institutional investors have recently made changes to their positions in FPRX. BlackRock Inc. lifted its stake in Five Prime Therapeutics by 4.4% during the 4th quarter. BlackRock Inc. now owns 3,039,915 shares of the biotechnology company’s stock worth $28,269,000 after acquiring an additional 127,777 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Five Prime Therapeutics by 5.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,484,178 shares of the biotechnology company’s stock worth $13,803,000 after purchasing an additional 71,001 shares during the period. Northern Trust Corp increased its holdings in Five Prime Therapeutics by 0.5% during the 4th quarter. Northern Trust Corp now owns 425,775 shares of the biotechnology company’s stock worth $3,959,000 after purchasing an additional 2,278 shares during the period. Geode Capital Management LLC increased its holdings in Five Prime Therapeutics by 10.4% during the 4th quarter. Geode Capital Management LLC now owns 409,701 shares of the biotechnology company’s stock worth $3,810,000 after purchasing an additional 38,601 shares during the period. Finally, Sofinnova Investments Inc. purchased a new stake in Five Prime Therapeutics during the 4th quarter worth about $2,933,000. 86.94% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ FPRX traded down $0.08 on Monday, reaching $5.06. 175,647 shares of the company were exchanged, compared to its average volume of 388,978. The firm has a fifty day simple moving average of $5.95. The company has a market cap of $185.37 million, a PE ratio of -1.23 and a beta of 2.67. The company has a debt-to-equity ratio of 0.21, a current ratio of 10.41 and a quick ratio of 10.41. Five Prime Therapeutics has a fifty-two week low of $4.90 and a fifty-two week high of $16.00.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.

Recommended Story: What is a growth and income fund?

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.